|
Welcome
|
|
07 August 2008
|
|
|
| home | my details | ISRCTN Register | mRCT | UKCTG | links | information | news |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
|
| [ ...Back to search results ] | [ Print-friendly version ] |
| A randomised, double-blind, placebo-controlled, dose-ranging two-centre study to evaluate the efficacy and safety of Devil's Claw in the treatment of knee and hip osteoarthritis |
| Source of record | UK Clinical Trials Gateway |
| ISRCTN | ISRCTN57843703 |
| Date ISRCTN assigned | 13/12/2006 |
| Local reference number(s) | Version 20 |
| Public title | A randomised, double-blind, placebo-controlled, dose-ranging two-centre study to evaluate the efficacy and safety of Devil's Claw in the treatment of knee and hip osteoarthritis |
| Scientific title | |
| Acronym | N/A |
| Disease/condition/study domain | Osteoarthritis of knee and/or hip |
| Study hypothesis | 1. Devil's Claw has anti-inflammatory properties (as assessed by the reduction in pain, stiffness and disability aspects on the Western Ontario and McMaster Universities Arthritis Index [WOMAC]) in chronic OsteoArthritis (OA) of the knee and/or hip after 16 weeks of treatment, as compared to placebo. 2. A dose response effect exists in the treatment of osteoarthritis of the knee/hip by Devil¿s Claw. |
| Design/methodology | A randomised, double-blind, placebo-controlled, dose-ranging two-centre study |
| Research ethics review | Southampton and South West Hampshire, Local Research Ethics Committees, approval: 14/04/2004 (ref: LREC 049/04/t) |
| Countries of trial | United Kingdom |
| Participants - inclusion criteria | 1. Patients with either a pragmatic diagnosis of: a. Osteoarthritis of the knee, with no other known rheumatological condition and who report the following clinical features (based on the American College of Rheumatology [ACR] classification for knee OA1): i. Knee pain on most days of the previous month ii. Morning stiffness of less than 30 minutes duration iii. ¿Stiffness¿ in resting the joint, and iv. Aged over 40 years b. Osteoarthritis of the hip, with no other known rheumatological condition and who report the following clinical features (based on the ACR classification for hip OA2) - hip pain on most days of the previous month and at least two of the following three features: i. Erythrocyte Sedimentation Rate (ESR) less than 20 mm/hour ii. Radiographic femoral or acetabular osteophytes iii. Radiographic joint space narrowing (superior, axial and/or medial), and iv. Aged over 45 years of age The diagnosis of osteoarthritis will be confirmed by X-ray. 2. Only patients who have grade 2 to 4 of the Kellgren and Lawrence scale will be recruited (The Kellgren and Lawrence scale ranges from grade zero to grade four where grades zero and one represent doubtful osteoarthritic changes and therefore a doubtful diagnosis). 3. Patients who have been on stable medication (conventional or complementary, including nutritional medicine) for the past three months, but are still getting symptoms (incomplete responders) 4. Only those patients who record baseline pain scores on the WOMAC scale of at least 20 mm on the Visual Analogue Scale (VAS) for a minimum of six out of seven days monitored during the period from Clinic Visit one (screening) and Clinic Visit two (baseline) 5. Ability to comply with the requirements of the study and to give informed consent 6. For women of child-bearing potential: negative pregnancy test |
| Participants - exclusion criteria | 1. Participation in an investigational trial within 30 days prior to enrolment 2. Previous treatment with Devil¿s Claw within 90 days prior to enrolment 3. Patients awaiting a replacement knee or hip joint 4. Patients with other conditions that cause pain 5. Patients with congenital dislocation of the hip 6. Patients who have had operations on their hip due to previous trauma 7. Patients with severe co-morbidities ¿ including severe cardiac or pulmonary disease and cancer 8. Dementia, psychoses, or other significant impairment of mental status that would prohibit sufficient comprehension, provision of informed consent and to allow undertaking of the necessary self-care or toxicity reporting 9. Patients taking corticosteroid medication 10. Known allergies against any of the ingredients of the treatments 11. Patients who would be unable to complete the self assessment forms, or to attend for X-ray and clinical examination 12. Patients with other known rheumatic disease such as rheumatoid arthritis 13. Patients with the diagnosis gout 14. Patients who report a red or hot swollen joint (which is unlikely to be due to OA), and would require further rheumatological assessment 15. Patients with conditions known to be contraindicated to the study medication i.e. patients with gastric or duodenal ulcers; gallstones; patients taking drugs for arrhythmias; patients with heart failure 16. Patients who are pregnant, trying to become pregnant or breastfeeding |
| Patient information material | |
| Anticipated start date | 12/12/2004 |
| Anticipated end date | 30/09/2008 |
| Status of trial | Stopped |
| Target number of participants | 264 |
| Interventions | Please note that this trial was terminated on 4 Jun 2007. Patients randomised to one of four groups: 1. Placebo medication 2. Devil's Claw (240 mg/d extract, equivalent dose of 2.4 - 4.8 mg/d) 3. Devil's Claw (960 mg/d extract, equivalent dose of 9.6 - 19.2 mg/d) 4. Devil's Claw (1920 mg/d extract, equivalent dose of 19.2 - 40.4 mg/d) |
| Primary outcome measure(s) | Reduction in WOMAC total score from baseline to week 16. |
| Secondary outcome measure(s) | 1. Secondary Efficacy Analysis 2. Change in WOMAC subscales (pain, stiffness, disability) from baseline to end of treatment at week 16 3. Quality of Life assessments (Short Form health survey [SF-36]) 4. Changes in the subject¿s well-being 5. Changes in subject's overall global assessment 6. Changes in attitudes and health beliefs to Complementary/Alternative Medicine (CAM) 7. Group differences between adverse event reporting |
| Sources of funding | 1. Southampton Complementary Medicine Research Trust (UK) 2. University of Southampton (UK) 3. Pascoe Pharmazeutische Praparate GmbH (Germany) |
| Sponsor name | University of Southampton (UK) |
| Sponsor details | University Road Highfield Southampton United Kingdom SO17 1BJ |
| Sponsor telephone | +44 (0)23 8059 8672 |
| Sponsor email | info@rso.soton.ac.uk |
| Sponsor website | http://www.soton.ac.uk/ |
| Contact name | Dr Sarah Brien |
| Contact details | Complementary Medicine Research Unit University of Southampton Aldermoor Health Centre Aldermoor Close Southampton United Kingdom SO16 5ST |
| Contact telephone | +44 (0)23 8024 1069 |
| Contact email | sbb@soton.ac.uk |
| More information | For more up-to-date information please go to the ISRCTN link below. |
| Link to record in ISRCTN Register | ISRCTN57843703 |
| Date last extracted from ISRCTN register | 17/04/2008 |
|
|
|
| terms & conditions | privacy statement | © Current Controlled Trials Ltd | |
|
|
|
|